DOCSLIB.ORG

Fluconazole, but Not Terbinafine, Enhances the Effects of Triazolam By

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fluconazole, but Not Terbinafine, Enhances the Effects of Triazolam By Br J Clin Pharmacol 1996; 41: 319–323 Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism ANU VARHE, KLAUS T. OLKKOLA & PERTTI J NEUVONEN Department of Clinical Pharmacology, University of Helsinki and University Central Hospital, Helsinki, Finland 1 The interaction between triazolam and two antifungal agents, fluconazole and terbinafine, was investigated in a double-blind, randomized crossover study of three phases. 2 Twelve healthy young volunteers received 100 mg fluconazole, 250 mg terbinafine or placebo orally once a day for 4 days. On day 4 they took a single 0.25 mg dose of triazolam. Plasma samples were collected and pharmacodynamic effects were measured up to 17 h after the intake of triazolam. 3 Fluconazole increased the area under the triazolam concentration time-curve more than twofold (P<0.001) and prolonged the elimination half-life of triazolam nearly twofold (P<0.001). The peak concentration of triazolam was also increased significantly (P<0.05) by fluconazole. 4 During the fluconazole phase pharmacodynamic effects of triazolam (e.g. digit symbol substitution test, body sway and drowsiness) were enhanced signifi- cantly (P<0.05) when compared with the placebo phase. 5 Terbinafine did not change significantly the pharmacokinetics or pharmacodyn- amics of triazolam. 6 Care should be taken when triazolam is prescribed to patients using fluconazole. Although the interaction is not as strong as that of triazolam with ketoconazole or itraconazole, it is clinically significant. Triazolam and probably other drugs metabolized by CYP3A4 can be used in normal doses with terbinafine. Keywords triazolam fluconazole terbinafine interaction pharmacokinetics pharmacodynamics Introduction fluconazole has been less susceptible than other azoles to interact with drugs metabolized by cytochrome P450 Triazolam, a widely used benzodiazepine hypnotic, has enzymes (e.g. terfenadine) [5–7]. Recent studies have an elimination half-life of 2 to 4 h and an oral shown, however, that fluconazole may also interact with bioavailability of approximately 60% [1]. Triazolam is some drugs which are metabolized by CYP3A4 [8–10]. metabolized in the liver and in the gut wall by Both fluconazole and terbinafine inhibit fungal growth cytochrome P450 3A4 [2]. Therefore inhibitors and by suppression of ergosterol biosynthesis. The mode of inducers of this isoenzyme may lead to drug interactions fluconazole action is the inhibition of the cytochrome with triazolam. Ketoconazole and itraconazole increase P-450 enzyme lanosterol 14-a-demethylase [11]. Ter- the AUC of oral triazolam more than 20-fold [3]. The binafine, an allylamine antimycotic, inhibits a non- elimination half-life of triazolam is also prolonged by cytochrome P-450 enzyme, squalene epoxidase [12]. these antimycotics. Terbinafine is only weakly bound to CYP450, and it The in vitro interaction potential of fluconazole with inhibits only slightly the metabolism of tolbutamide, many substrates of CYP3A4 is considerably less than ethinyloestradiol, cyclosporin and ethoxycoumarin [13]. that of ketoconazole or itraconazole [4]. Also in vivo, Because triazolam is often used by patients on antimy- Correspondence: Dr. Anu Varhe, Department of Clinical Pharmacology, University of Helsinki, Paasikivenkatu 4, FIN-00250 Helsinki, Finland © 1996 Blackwell Science Ltd 319 320 Anu Varhe et al. cotic therapy, we have studied the effects of fluconazole concentration-time curve was identified visually for each and terbinafine on the pharmacokinetics and pharmaco- subject. The elimination rate constant (l ) was deter- z dynamics of triazolam in healthy volunteers. mined by regression analysis of the log-linear part of the curve. The elimination half-life (t ) was calculated 1/2,z from t ln2/l . The areas under the triazolam 1/2,z= z concentration-time curves (AUC(0,17 h)) were calculated Methods using the linear trapezoidal rule, with extrapolation to infinity (AUC) [18]. Study design Twelve healthy volunteers (10 females and two males) Pharmacodynamic measurements aged 19–31 years and weighing 48–80 kg gave written informed concent to participate in this study. The study Pharmacodynamic effects of triazolam were assessed at protocol and the consent form were approved by the the time of blood sampling by use of a battery of tests: Ethics Committee of the Department of Clinical the digit symbol substitution test, DSST, the critical Pharmacology, University of Helsinki and Finnish flicker fusion test, the Maddox wing test, subjective National Agency for Medicines. A randomized, double- drowsiness ( VAS) and body sway with eyes open and blind, cross-over study design in three phases was used. eyes closed, as described earlier [3]. For each pharmaco- The phases were separated by an interval of 4 weeks. dynamic variable, the areas under the response-time The subjects were given orally either 100 mg fluconazole curves were determined by the trapezoidal rule from 0 (Diflucan, Pfizer, Amboise, France), 250 mg terbinafine to 7 h (AUC(0,7 h)). (Lamisil, Sandoz, Basle, Switzerland), or placebo orally at 14.00 h daily for 4 days. On day 4, the subjects ingested a single 0.25 mg oral dose of triazolam (Halcion, Statistics Upjohn, Kalamazoo, MI, USA) with 150 ml water at 15.00 h. The volunteers fasted for 3 h before adminis- The results are expressed as mean values±s.e.mean, and tration of triazolam and had a standard meal 4 h 95% confidence intervals on major differences between afterward. Tobacco, as well as ingestion of alcohol, tea, the phases were calculated. ANOVA with repeated coffee and cola was forbidden during the test days. measures was used; a posteriori testing was done by the Eight of the 10 female subjects used oral contraceptive Tukey’s test. The t values were compared with max steroids. Other concomitant drugs were not used. Friedman’s two-way ANOVA and the Wilcoxon signed- rank test. Pearson’s product-moment correlation coefficient was used to investigate possible relationship Blood sampling and determination of drugs in plasma between the ratio of the AUC(0,17 h) of triazolam during the fluconazole phase to the AUC(0,17 h) during On day 4, blood was sampled into EDTA-tubes before the placebo phase versus the C of fluconazole. max administration of triazolam and 0.5, 1, 1.5, 2, 3, 4, 5, 6, Differences were regarded as statistically significant if P 7 and 17 h afterward. Plasma was separated within 30 values were <0.05. Systat for Windows, a statistical min and stored at −20° C until triazolam and anti- program, was used for the analyses of the data. mycotic concentrations were analysed. Plasma triazolam concentrations were determined by gas chromatography with use of a modified method of DeKroon et al. [14, 15]. The sensitivity of the method was 0.1 ng ml−1. Results The coefficient of day-to-day variation was 11.6% (at 0.34 ng ml−1, n=11). Plasma samples for antimycotic Pharmacokinetics determinations were taken 1, 1.5, 3, 5, 8 and 18 h after their fourth (=last) dose (i.e. before and 0.5, 2, 4, 7 and Fluconazole increased the mean AUC more than 17 h after the administration of triazolam). Terbinafine twofold, from a control value of 12.2±1.4 ng ml−1 h and fluconazole concentrations were determined by to 30.0±2.6 ng ml−1 h(P<0.001) (Table, Figure 1). h.p.l.c. with u.v.-detection [16, 17]. The sensitivity of The t of triazolam was prolonged nearly twofold 1/2,z the method for terbinafine was 10 ng ml 1 and the (P 0.001), and the C of triazolam was also increased − < max coefficient of day-to-day variation was 3.5% (at by fluconazole (P<0.05). Despite considerable interindi- 248 ng ml−1, n=6). The sensitivity of the fluconazole vidual differences in the extent of interaction, fluconazole method was 100 ng ml−1 and the coefficient of day-to- increased the AUC(0,17 h) in each subject. The ratio of day variation 1.3% (at 3.9 mg l−1,n=7). the AUC(0,17 h) of triazolam during the fluconazole phase to the AUC(0,17 h) during the placebo phase ranged from 1.3 to 4.3. Pharmacokinetics of triazolam Terbinafine did not change any of the pharmacokinetic variables of triazolam to a statistically significant degree Peak-concentrations (C ) and concentration peak (Figure 1, Table 1). In nine of the 12 subjects the max times (t ) were derived directly from the original AUC(0,17 h) of triazolam was smaller during the max values. The terminal log-linear phase of the plasma terbinafine phase than during the placebo phase. The © 1996 Blackwell Science Ltd British Journal of Clinical Pharmacology 41, 319–323 Fluconazole, but not terbinafine, interacts with triazolam 321 Table The pharmacokinetic variables of triazolam 0.25 mg (mean±s.e.mean or median and range) following pretreatment with oral fluconazole 100 mg, terbinafine 250 mg or placebo for 4 days in 12 healthy volunteers. In parentheses are the 95% confidence intervals for the differences from the placebo phase. Variable Placebo (Control) Fluconazole phase T erbinafine phase C (ng ml 1) 2.0 0.2 2.5 0.2† (0.1, 1.1) 1.7 0.2( 0.7, 0.2) max − ± ± ± − (% of control) (100) (125) (85) t (h) 1.8 (0.5, 2.0)* 2.0 (1.0, 4.0)* 1.5 (0.5, 3.0)* max AUC(0,17 h) (ng ml−1 h) 11.5±1.3 24.1±1.8‡ (9.0, 16.2) 9.8±1.3 (−4.0, 0.4) (% of control) (100) (210) (85) AUC (ng ml−1 h) 12.2±1.4 30.0±2.6‡ (13.1, 22.8) 9.9±1.2 (−4.7, 0.1) (% of control) (100) (246) (81) t (h) 3.7 0.3 6.8 0.6‡ (1.7, 4.4) 3.2 0.3 ( 0.8, 0.2) 1/2,z ± ± ± − − (% of control) (100) (184) (86) * Median (range).
Load more

Recommended publications
  • Voriconazole
    Drug and Biologic Coverage Policy Effective Date ............................................ 6/1/2020 Next Review Date… ..................................... 6/1/2021 Coverage Policy Number .................................. 4004 Voriconazole Table of Contents Related Coverage Resources Coverage Policy ................................................... 1 FDA Approved Indications ................................... 2 Recommended Dosing ........................................ 2 General Background ............................................ 2 Coding/Billing Information .................................... 4 References .......................................................... 4 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion
    [Show full text]
  • Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut
    ■ CLINICAL REVIEW Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut Tinea versicolor (pityriasis versicolor) is a common imidazole, has been used for years both orally and top­ superficial fungal infection of the stratum corneum. ically with great success, although it has not been Caused by the fungus Malassezia furfur, this chronical­ approved by the Food and Drug Administration for the ly recurring disease is most prevalent in the tropics but indication of tinea versicolor. Newer derivatives, such is also common in temperate climates. Treatments are as fluconazole and itraconazole, have recently been available and cure rates are high, although recurrences introduced. Side effects associated with these triazoles are common. Traditional topical agents such as seleni­ tend to be minor and low in incidence. Except for keto­ um sulfide are effective, but recurrence following treat­ conazole, oral antifungals carry a low risk of hepato- ment with these agents is likely and often rapid. toxicity. Currently, therapeutic interest is focused on synthetic Key Words: Tinea versicolor; pityriasis versicolor; anti­ “-azole” antifungal drugs, which interfere with the sterol fungal agents. metabolism of the infectious agent. Ketoconazole, an (J Fam Pract 1996; 43:127-132) ormal skin flora includes two morpho­ than formerly thought. In one study, children under logically discrete lipophilic yeasts: a age 14 represented nearly 5% of confirmed cases spherical form, Pityrosporum orbicu- of the disease.3 In many of these cases, the face lare, and an ovoid form, Pityrosporum was involved, a rare manifestation of the disease in ovale. Whether these are separate enti­ adults.1 The condition is most prevalent in tropical tiesN or different morphologic forms in the cell and semitropical areas, where up to 40% of some cycle of the same organism remains unclear.: In the populations are affected.
    [Show full text]
  • Stability of Two Antifungal Agents, Fluconazole and Miconazole, Compounded in HUMCO RECURA Topical Cream to Determine Beyond-Use Date
    PEER REVIEWED Stability of Two Antifungal Agents, Fluconazole and Miconazole, Compounded in HUMCO RECURA Topical Cream to Determine Beyond-use Date ABSTRACT Pradeep Gautam, MS Chemistry A novel compounding vehicle (RECURA) has previously been proven to Bob Light, BS, RPh penetrate the nail bed when compounded with the antifungal agent miconazole or fluconazole, providing for an effective treatment for onychomycosis. In this Troy Purvis, PhD study, miconazole and fluconazole were compounded separately in RECURA compounding cream, and they were tested at different time points (0, 7, 14, 28, 45, 60, 90, and 180 days), determining the beyond-use date of those INTRODUCTION formulations. The beyond-use date testing of both formulations (10% Onychomycosis is a fungal infection of miconazole in RECURA and 10% fluconazole in RECURA) proved them to be the nail bed in the fingers, or more com- physically, chemically, and microbiologically stable under International monly the toes, which affects an estimated Conference of Harmonisation controlled room temperature (25°C ± 2°C/60% 1 10% of the world’s population. Trichophy- RH ±5%) for at least 180 days from the date of compounding. Stability- ton is the typical fungal genus that causes indicating analytical method validation was completed for the simultaneous these infections in Western countries, while determination of miconazole and fluconazole in RECURA base using high- those living tropical regions experience Candida, Aspergillus, or Scytaldium infec- performance liquid chromatography coupled with photodiode array detector tion,2 but the symptoms of these infections prior to the study. are similar across the board. Minor infec- tion causes a yellow or black thickening of the nail bed, while further progression can 48% cure rate),1 yet concern about long- These medications must be in direct contact result in the nail chipping away and leaving term dosing and severe side-effects due to with the fungus in order to kill it.5 The FDA- an open sore, leading to secondary infec- oral administration exists.
    [Show full text]
  • The Epidemiology and Clinical Features of Balamuthia Mandrillaris Disease in the United States, 1974 – 2016
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Clin Infect Manuscript Author Dis. Author manuscript; Manuscript Author available in PMC 2020 August 28. Published in final edited form as: Clin Infect Dis. 2019 May 17; 68(11): 1815–1822. doi:10.1093/cid/ciy813. The Epidemiology and Clinical Features of Balamuthia mandrillaris Disease in the United States, 1974 – 2016 Jennifer R. Cope1, Janet Landa1,2, Hannah Nethercut1,3, Sarah A. Collier1, Carol Glaser4, Melanie Moser5, Raghuveer Puttagunta1, Jonathan S. Yoder1, Ibne K. Ali1, Sharon L. Roy6 1Waterborne Disease Prevention Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA 2James A. Ferguson Emerging Infectious Diseases Fellowship Program, Baltimore, MD, USA 3Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA 4Kaiser Permanente, San Francisco, CA, USA 5Office of Financial Resources, Centers for Disease Control and Prevention Atlanta, GA, USA 6Parasitic Diseases Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA Abstract Background—Balamuthia mandrillaris is a free-living ameba that causes rare, nearly always fatal disease in humans and animals worldwide. B. mandrillaris has been isolated from soil, dust, and water. Initial entry of Balamuthia into the body is likely via the skin or lungs. To date, only individual case reports and small case series have been published. Methods—The Centers for Disease Control and Prevention (CDC) maintains a free-living ameba (FLA) registry and laboratory. To be entered into the registry, a Balamuthia case must be laboratory-confirmed.
    [Show full text]
  • DIFLUCAN® (Fluconazole Tablets) (Fluconazole for Oral Suspension)
    ® DIFLUCAN (Fluconazole Tablets) (Fluconazole for Oral Suspension) DESCRIPTION DIFLUCAN® (fluconazole), the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration, as a powder for oral suspension. Fluconazole is designated chemically as 2,4-difluoro-α,α1-bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with an empirical formula of C13H12F2N6O and molecular weight of 306.3. The structural formula is: OH N N N N CH2 C CH2 N F N F Fluconazole is a white crystalline solid which is slightly soluble in water and saline. DIFLUCAN Tablets contain 50 mg, 100 mg, 150 mg, or 200 mg of fluconazole and the following inactive ingredients: microcrystalline cellulose, dibasic calcium phosphate anhydrous, povidone, croscarmellose sodium, FD&C Red No. 40 aluminum lake dye, and magnesium stearate. DIFLUCAN for Oral Suspension contains 350 mg or 1400 mg of fluconazole and the following inactive ingredients: sucrose, sodium citrate dihydrate, citric acid anhydrous, sodium benzoate, titanium dioxide, colloidal silicon dioxide, xanthan gum, and natural orange flavor. After reconstitution with 24 mL of distilled water or Purified Water (USP), each mL of reconstituted suspension contains 10 mg or 40 mg of fluconazole. CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism The pharmacokinetic properties of fluconazole are similar following administration by the intravenous or oral routes. In normal volunteers, the bioavailability of orally administered fluconazole is over 90% compared with intravenous administration. Bioequivalence was Reference ID: 4387685 established between the 100 mg tablet and both suspension strengths when administered as a single 200 mg dose. Peak plasma concentrations (Cmax) in fasted normal volunteers occur between 1 and 2 hours with a terminal plasma elimination half-life of approximately 30 hours (range: 20 to 50 hours) after oral administration.
    [Show full text]
  • Treatment of Visceral Leishmaniasis with Intravenous Pentamidine And
    International Journal of Infectious Diseases 14 (2010) e522–e525 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Case Report Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure — a case report and brief review of the literature Jan Rybniker a, Valentin Goede a, Jessica Mertens b, Monika Ortmann c, Wolfgang Kulas d, Matthias Kochanek a, Thomas Benzing e, Jose´ R. Arribas f, Gerd Fa¨tkenheuer a,* a 1st Department of Internal Medicine, University of Cologne, 50924 Cologne, Germany b Department of Gastroenterology, University of Cologne, Cologne, Germany c Institute of Pathology, University of Cologne, Cologne, Germany d Nephrologisches Zentrum Mettmann, Mettmann, Germany e Department of Medicine and Centre for Molecular Medicine, University of Cologne, Cologne, Germany f Enfermedades Infecciosas, Hospital Universitario La Paz, Madrid, Spain ARTICLE INFO SUMMARY Article history: We report the case of an HIV-positive patient with visceral leishmaniasis and several relapses after Received 3 March 2009 treatment with the two first-line anti-leishmanial drugs, liposomal amphotericin B and miltefosine. End- Accepted 4 June 2009 stage renal failure occurred in 2007 when the patient was on long-term treatment with miltefosine. A Corresponding Editor: William Cameron, relapse of leishmaniasis in 2008 was successfully treated with a novel combination regimen of Ottawa, Canada intravenous pentamidine and oral fluconazole. Secondary prophylaxis with fluconazole monotherapy did not prevent parasitological relapse of leishmaniasis. Keywords: ß 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Visceral leishmaniasis HIV Fluconazole Pentamidine Miltefosine Renal failure 1.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Cutaneous Sporotrichosis of Face: Polymorphism and Reactivation After Intralesional Triamcinolone
    Case Report CCutaneousutaneous sporotrichosissporotrichosis ofof face:face: PolymorphismPolymorphism andand reactivationreactivation afterafter iintralesionalntralesional triamcinolonetriamcinolone NNandand LLalal Sharma,Sharma, KKaranaran InderInder SSinghingh MMehta,ehta, VVikramikram K.K. MMahajan,ahajan, AAnilnil KK.. KKanga*,anga*, VVikasikas CChanderhander SSharma,harma, GitaGita RR.. TTegtaegta Departments of Dermatology, Venereology and Leprosy and *Microbiology, Indira Gandhi Medical College, Shimla, India. Address for correspondence: Dr. N. L. Sharma, Department of Dermatology, Venereology and Leprosy, Indira Gandhi Medical College, Shimla - 171001 (H. P.), India. E-mail: [email protected] ABSTRACT Cutaneous sporotrichosis, a subcutaneous mycotic infection is caused by the saprophytic, dimorphic fungus Sporothrix schenckii. It commonly presents as lymphocutaneous or fixed cutaneous lesions involving the upper extremities with facial lesions being seen more often in children. The lesions are polymorphic. The therapeutic response to saturated solution of potassium iodide is almost diagnostic.We describe a culture-proven case of cutaneous sporotrichosis of the face mimicking lupus vulgaris initially and basal cell carcinoma later, who did not tolerate potassium iodide and failed to respond to treatment with fluconazole. The patient had reactivation of infection following an infiltration of the scar with triamcinolone acetonide injection. Various other aspects of these unusual phenomena are also discussed. .com). Key Words: Cicatricial
    [Show full text]
  • Miltefosine Treatment Reduces Visceral Hypersensitivity in a Rat Model For
    www.nature.com/scientificreports OPEN Miltefosine treatment reduces visceral hypersensitivity in a rat model for irritable bowel syndrome Received: 28 February 2019 Accepted: 2 August 2019 via multiple mechanisms Published: xx xx xxxx Sara Botschuijver1, Sophie A. van Diest1, Isabelle A. M. van Thiel 1, Rafael S. Saia1,2, Anne S. Strik1,3, Zhumei Yu1,4,9, Daniele Maria-Ferreira 1,5, Olaf Welting1, Daniel Keszthelyi6, Gary Jennings7, Sigrid E. M. Heinsbroek1,3, Ronald P. Oude Elferink 1,3, Frank H. J. Schuren 8, Wouter J. de Jonge1,3 & René M. van den Wijngaard1,3 Irritable bowel syndrome (IBS) is a heterogenic, functional gastrointestinal disorder of the gut-brain axis characterized by altered bowel habit and abdominal pain. Preclinical and clinical results suggested that, in part of these patients, pain may result from fungal induced release of mast cell derived histamine, subsequent activation of sensory aferent expressed histamine-1 receptors and related sensitization of the nociceptive transient reporter potential channel V1 (TRPV1)-ion channel. TRPV1 gating properties are regulated in lipid rafts. Miltefosine, an approved drug for the treatment of visceral Leishmaniasis, has fungicidal efects and is a known lipid raft modulator. We anticipated that miltefosine may act on diferent mechanistic levels of fungal-induced abdominal pain and may be repurposed to IBS. In the IBS-like rat model of maternal separation we assessed the visceromotor response to colonic distension as indirect readout for abdominal pain. Miltefosine reversed post-stress hypersensitivity to distension (i.e. visceral hypersensitivity) and this was associated with diferences in the fungal microbiome (i.e. mycobiome).
    [Show full text]
  • Limited Activity of Miltefosine in Murine Models of Cryptococcal Meningoencephalitis and Disseminated Cryptococcosis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UT Digital Repository Limited Activity of Miltefosine in Murine Models of Cryptococcal Meningoencephalitis and Disseminated Cryptococcosis Nathan P. Wiederhold,a,b Laura K. Najvar,a,c Rosie Bocanegra,a,c William R. Kirkpatrick,a,c Tania C. Sorrell,d,e,f Thomas F. Pattersona,c University of Texas Health Science Center at San Antonio, San Antonio, Texas, USAa; University of Texas at Austin College of Pharmacy, Austin, Texas, USAb; South Texas Veterans Health Care Administration, San Antonio, Texas, USAc; Sydney Emerging Infections and Biosecurity Institute, Sydney, Australiad; University of Sydney, Sydney, Australiae; Westmead Millennium Institute, Sydney, Australiaf Miltefosine is an alkyl phosphocholine with good oral bioavailability and in vitro activity against Cryptococcus species that has gained interest as an additional agent for cryptococcal infections. Our objective was to further evaluate the in vivo efficacy of miltefosine in experimental in vivo models of cryptococcal meningoencephalitis and disseminated cryptococcosis. Mice were infected intracranially or intravenously with either C. neoformans USC1597 or H99. Miltefosine treatment (1.8 to 45 mg/kg of body weight orally once daily) began at either1hor1daypostinoculation. Fluconazole (10 mg/kg orally twice daily) or ampho- tericin B deoxycholate (3 mg/kg intraperitoneally once daily) served as positive controls. In our standard models, miltefosine did not result in significant improvements in survival or reductions in fungal burden against either C. neoformans isolate. There was a trend toward improved survival with miltefosine at 7.2 mg/kg against disseminated cryptococcosis with the H99 strain but only at a low infecting inoculum.
    [Show full text]
  • Fluconazole Versus Itraconazole for the Prevention of Fungal Infections
    376 J Clin Pathol 1999;52:376–380 Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology J Clin Pathol: first published as 10.1136/jcp.52.5.376 on 1 May 1999. Downloaded from P C Huijgens, A M Simoons-Smit, A C van Loenen, E Prooy, H van Tinteren, G J Ossenkoppele, A R JonkhoV Abstract Superficial and disseminated fungal disease Aims—To compare the eYcacy of and tol- remains a challenging problem for clinicians erance to oral fluconazole and intracona- caring for neutropenic patients with haemato- zole in preventing fungal infection in logical malignancies.1–4 It is the most important neutropenic patients with haematological cause of morbidity and mortality, and because malignancies. it is diYcult to detect, most centres give intra- Patients—213 consecutive, afebrile adult venous antifungal agents to febrile patients patients treated with or without autolo- who do not readily respond to antibacterial 5–7 gous stem cell transplantation for haema- treatment. tological malignancies. Antifungal prophylaxis is widely used. Oral amphotericin has been used in doses of around Methods—A randomised, double blind, 1 to 3 g daily. Its acceptability to patients is single centre study. Patients were ran- poor. In randomised trials, oral polyenes did domly assigned to receive fluconazole 50 not prevent haematogenous candidiasis.8–11 mg or itraconazole 100 mg, both twice Fluconazole has emerged as the most widely daily in identical capsules. An intention to used prophylactic agent in neutropenic pa- treat analysis was performed on 202 tients. The drug eVectively prevents oropha- patients, 101 in each group.
    [Show full text]
  • Evidence-Based Danish Guidelines for the Treatment of Malassezia- Related Skin Diseases
    Acta Derm Venereol 2015; 95: 12–19 SPECIAL REPORT Evidence-based Danish Guidelines for the Treatment of Malassezia- related Skin Diseases Marianne HALD1, Maiken C. ARENDRUP2, Else L. SVEJGAARD1, Rune LINDSKOV3, Erik K. FOGED4 and Ditte Marie L. SAUNTE5; On behalf of the Danish Society of Dermatology 1Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, 2 Unit for Mycology, Statens Serum Institut, 3The Dermatology Clinic, Copen- hagen, 4The Dermatology Clinic, Holstebro, and 5Department of Dermatology, Roskilde Hospital, University of Copenhagen, Denmark Internationally approved guidelines for the diagnosis including those involving Malassezia (2), guidelines and management of Malassezia-related skin diseases concerning the far more common skin diseases are are lacking. Therefore, a panel of experts consisting of lacking. Therefore, a panel of experts consisting of dermatologists and a microbiologist under the auspi- dermatologists and a microbiologist appointed by the ces of the Danish Society of Dermatology undertook a Danish Society of Dermatology undertook a data review data review and compiled guidelines for the diagnostic and compiled guidelines on the diagnostic procedures procedures and management of pityriasis versicolor, se- and management of Malassezia-related skin diseases. borrhoeic dermatitis and Malassezia folliculitis. Main The ’head and neck dermatitis’, in which hypersensi- recommendations in most cases of pityriasis versicolor tivity to Malassezia is considered to be of pathogenic and seborrhoeic dermatitis include topical treatment importance, is not included in this review as it is restric- which has been shown to be sufficient. As first choice, ted to a small group of patients with atopic dermatitis. treatment should be based on topical antifungal medica- tion.
    [Show full text]